Cathie Wood's ARK sells Roku, buys Caris Life Sciences stock

Cathie Wood’s ARK ETFs disclosed their July 14, 2025 daily trades, showcasing significant portfolio rebalancing with notable sales and a new strategic investment. The funds continued to reduce exposure to Roku Inc. (ROKU) by divesting 33,963 shares valued at over $3 million, while also selling shares of Archer Aviation Inc. (ACHR) and Guardant Health Inc. (GH). Concurrently, ARK's ARKG ETF initiated a new position in Caris Life Sciences Inc. (CAI) with a $1.4 million purchase, signaling an evolving focus within the healthcare sector despite other sector divestments. These moves offer insights into ARK's shifting convictions and dynamic investment approach.

Analysis

ARK Invest's trading activity on July 14, 2025, reveals a significant rebalancing of its portfolio, characterized by continued divestment from specific technology and healthcare holdings and a strategic new investment in a private biotech firm. The fund's sale of 33,963 Roku shares for approximately $3.0 million and 171,557 Archer Aviation shares for $1.8 million extends a pattern of consistent selling, suggesting diminishing conviction in these names. Within the healthcare sector, ARK's strategy appears highly selective; while it divested 27,569 shares of Guardant Health for nearly $1.4 million, it concurrently initiated a new position in private entity Caris Life Sciences, acquiring 52,527 shares for a similar value of $1.4 million. This targeted purchase, a new direction for the fund, indicates a specific preference within the life sciences space rather than a broad exit from the healthcare sector. The overall activity points to a dynamic rotation, shifting capital from publicly-traded companies with recently reduced exposure towards new, potentially earlier-stage opportunities.

Key Decisions for Investors

• Investors holding Roku (ROKU) and Archer Aviation (ACHR) should recognize the persistent selling pressure from a major institutional holder like ARK as a potential headwind and a signal of the fund's lowered conviction.
• The conflicting moves within healthcare—selling Guardant Health (GH) while buying Caris Life Sciences (CAI)—suggests that a company-specific, rather than a broad sector-based, approach is critical for this industry at present.
• Monitor ARK's future trades for continued accumulation in Caris Life Sciences or similar private biotech firms, as this may indicate a larger strategic pivot towards private market opportunities within their innovation theme.